Navigation Links
Mirixa Australia Achieves Six Month Milestones
Date:11/17/2009

ed that after only 12 weeks of program implementation, over 60% of patients had an improvement in medication adherence as measured by their MedsIndex score, and the average adherence improvement across all enrolled patients exceeded 25 percent.

"Medication non-adherence both here in Australia and worldwide represents a key source of both excess cost and suboptimal health outcomes," noted Kos Sclavos, National President of the Pharmacy Guild of Australia. "While we're still early in the game, we're very pleased with the results we're seeing. We have been waiting to see the 12 week result which coincides with the second patient consultation and these results exceed our expectation. The MedsIndex trend measured thus far encourages us that we're on the right track. We applaud the pharmacies and program sponsors who have come along with us on this journey to pioneer and prove a new model for pharmacy delivered services across Australia - and encourage others to join their colleagues in this national effort to demonstrate the profound and positive impact pharmacists can have in improving patient care outcomes," added Mr. Sclavos.

About Mirixa

Mirixa Corporation, sponsored by the National Community Pharmacists Association (NCPA), is the leader in targeted patient care services delivered via the nation's largest pharmacy-based patient care network. Dedicated to improving patients' health, Mirixa enables the healthcare community to deliver patient care services through retail pharmacy. The MirixaPro(SM) web-based clinical platform is used by pharmacists to deliver standardized patient care services. For more information, please visit www.Mirixa.com.

About The Pharmacy Guild of Australia

The Pharmacy Guild of Australia was established in 1928, bringing together several small retail pharmacy organizations then operating
'/>"/>

SOURCE Mirixa Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mirixa Corporation Announces MirixaEdge(SM)
2. Mirixa Corporation Announces Key Pharmacy Network Hire
3. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
4. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
5. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
6. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
7. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
8. New Australian Technology: Detecting Breast Cancer With Hair
9. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Valeant Pharmaceuticals International, ... the closing of its previously announced registered offering of ... (the "Offering"). Pursuant to the Offering, the Company ... per share, for aggregate gross proceeds of approximately $1.45 ... the U.S. Securities and Exchange Commission a final prospectus ...
(Date:3/27/2015)... March 27, 2015 As of February, ... incontinence devices for women. "Shipping thousands ... gratifying part is the hundreds of letters, emails ... lives have been positively impacted by our technology," ... InControl recently released Apex, an over-the-counter ...
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... in Improving Symptoms and Urine Flow, With,Long Lasting ... 23, 2007 /PRNewswire-FirstCall/ -- Spectrum,Pharmaceuticals, Inc., today announced ... Company's drug candidate for the treatment,of benign prostatic ... held at the Anaheim Convention Center in,Anaheim, California ...
... WIRE)--May 23, 2007 - Northfield,Laboratories, Inc. (NASDAQ: ... III trauma trial with PolyHeme(R), its human,hemoglobin-based ... designed to seek an indication for use ... loss when transfusion is,required and red blood ...
Cached Medicine Technology:Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 3Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 4Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 5Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 6Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 7Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 8
(Date:3/29/2015)... 2015 The Contract Research Organizations ... research, manage data results and help develop and ... regulation standards. Contract research organizations (CROs) mainly serve ... sectors. Industry operators provide clients with a full ... research for Food and Drug Administration (FDA) approval. ...
(Date:3/29/2015)... Franklin, TN (PRWEB) March 29, 2015 ... for several PT Online Continuing Education Courses . ... - 10.0 hours of CME - TPTA, approval # ... Master the evaluation of the shoulder complex - 10.5 ... Course Approved #56400TX , Examination and Treatment of the ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... game with knights, nature, and peasants. , The ... to Eurogamer. The popularity of these games grew over ...
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 Emergency ... offers urgent care in Manhattan, recently commemorated its three-year ... facility in Manhattan. In addition to 24-hour urgent care, ... facilities. , At this time, Emergency Medical Care’s ... abdominal pain, asthma, chest pain, eye injuries, ear infections, ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 One ... re-injury, according to research presented today at the American ... Day. The study examined the long term success of ... , “We examined survey data from 242 patients who ... author Justin P. Roe, MBBS, FRACS, from North Sydney ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... Gardasil, study finds, , TUESDAY, Aug. 18 (HealthDay News) ... a cause of cervical cancer, appears safe, with relatively ... government study. , The study, which included data ... found that the rate of serious adverse events for ...
... ... specializing in healthy and natural dog treats announced today the official launch of its ... for a qualified veterinarian. All licensed U.S. veterinarians may list their practice in ... ...
... BURLINGTON, Mass., Aug. 18 Palomar Medical Technologies, ... developer of light-based systems for cosmetic treatments, announced today that ... confirmed the validity of all claims in the re-examination of ... Removal Using Optical Pulses." , , Rejecting ...
... , OAKLAND, Calif., Aug. 18 The ... Older Adults Maintain Independence: Advancing Technology Adoption," a briefing paper ... chronic health care and increasing the independence of older adults, ... "Spending on hospitalizations and chronic care management now exceeds ...
... , Price of Diabetes Prevention ... , , BETHESDA, Md., Aug. 18 ... with diabetes has been misconstrued during recent health care reform ... nation,s leading professional organization of doctors of podiatric medicine (DPMs), ...
... , , , ... (JCMC), the 488 bed, Magnet-designated flagship hospital of Mountain States Health Alliance (MSHA), ... Smart S q uare , the enterprise scheduling software ... live with Smart Square, JCMC has realized a savings of nearly $550,000 associated ...
Cached Medicine News:Health News:Cervical Cancer Vaccine Seems Safe 2Health News:Cervical Cancer Vaccine Seems Safe 3Health News:FidoDogTreats.com Launches Veterinarian Directory 2Health News:Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent 2Health News:Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent 3Health News:Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent 4Health News:Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent 5Health News:Center for Technology and Aging Brief Reviews Technologies That Improve Chronic Care and Help Older Adults Maintain Independence 2Health News:Center for Technology and Aging Brief Reviews Technologies That Improve Chronic Care and Help Older Adults Maintain Independence 3Health News:American Podiatric Medical Association Corrects President's Misstatement on Foot Amputation Costs 2Health News:Johnson City Medical Center Saves $550,000 with Smart Square(R) 2
... immunometric ('sandwich') EIA for the quantitative ... or plasma. LH in the sample ... antibodies directed at different epitopes. One ... and the other is labelled with ...
For the quantitative determination of luteinizing hormone (LH) concentration in human serum....
... a glycoprotein secreted by the anterior pituitary ... the intact LH molecule is a noncovalently-linked ... all have homologous alpha-subunits, however each hormone ... FSH production and secretion are stimulated by ...
Microwell-EIA for the detection of GAD Autoantibody....
Medicine Products: